Polypeptides binding ADAMTS5, MMP13 and aggrecan

US11813307B2 · kind B2 · utility

Assignees

• Merck Patent GmbH · DE
• Ablynx N.V. · BE

Inventors

• Soren Steffensen · Woluwe-Saint-Pierre - Sint-Pieters-Woluwe, BE
• Gerald Beste · Evergem, BE
• Hans Guehring · Eltville am Rhein, DE
• Lars Toleikis · Kleinniedesheim, DE
• Christoph H. Ladel · Darmstadt, DE
• Sven Lindemann · Darmstadt, DE
• Roland Kellner · Heppenheim, DE
• Ralf Guenther · Griesheim, DE

Key dates

• Filing date: Jun 4, 2018
• Grant date: Nov 14, 2023
• Expiry date: Mar 8, 2039

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/33
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to polypeptides binding Aggrecan as well as ADAMTS5 and/or MMP13, more in particular to polypeptides that comprise or essentially consist of immunoglobulins binding Aggrecan as well as immunoglobulins binding ADAMTS5 and/or immunoglobulins binding MMP13 (also referred to herein as “polypeptides of the invention”, and “immunoglobulin(s) of the invention”, respectively). The invention also relates to constructs comprising such immunoglobulins, such as immunoglobulin single variable domains (ISVDs) or polypeptides as well as nucleic acids encoding such immunoglobulins or polypeptides (also referred to herein as “nucleic acid(s) of the invention”; to methods for preparing such immunoglobulins, polypeptides and constructs; to host cells expressing or capable of expressing such immunoglobulins or polypeptides; to compositions, and in particular to pharmaceutical compositions, that comprise such immunoglobulins, polypeptides, constructs, nucleic acids and/or host cells; and to uses of immunoglobulins, polypeptides, constructs, nucleic acids, host cells and/or compositions, in particular for prophylactic and/or therapeutic purposes, such as the prophylactic an…